If you could pay to live forever, would you? The question is no longer just a thought experiment or a story from mythology. For a growing number of billionaires, wellness influencers, and start-ups, immortality has become a business model. From Silicon Valley venture capitalists investing in anti-ageing biotech to social media personalities selling mushroom powders and peptides, the longevity industry is booming. Yet beneath the glossy marketing lies a host of hidden risks, from overdiagnosis to economic strain, that could leave society paying a steep price for the dream of eternal youth.
The Myth and the Market
Humanity’s fascination with immortality is as old as storytelling itself. Ancient Greek myths warned of the perils of life without death: Tithonus, granted eternal life without eternal youth, became trapped in endless decline. Today’s tech billionaires echo this age-old pursuit but with a modern arsenal of full-body scans, cryotherapy chambers, and blood plasma transfusions.
The industry now spans supplements, gene therapies, and wearable devices promising to “reverse” biological age. Bryan Johnson, a U.S. venture capitalist, has become the poster child of this movement, reportedly spending millions on his anti-ageing regimen that includes hundreds of supplements, a hyper-controlled diet, and experimental treatments such as plasma infusions.
While such stories make headlines, the question remains: does any of this actually work? Evidence suggests not—and that is where the danger begins.
Profit Before Proof
The longevity market thrives on innovation, but innovation is not the same as evidence. Many of the industry’s most popular interventions—from full-body MRI scans to genetic profiling—lack robust clinical backing.
Take full-body MRI, marketed as a tool for early cancer detection. Medical colleges across the world, including in Australia, advise against using such scans in healthy individuals. Research shows they often reveal “incidentalomas”—harmless anomalies that trigger cascades of unnecessary follow-up tests, costs, and anxiety.
This illustrates the profit-before-proof model: companies market advanced technology directly to consumers, bypassing medical consensus, while reaping revenue from fear of ageing. The public, seduced by promises of control over mortality, becomes both customer and test subject.
The Hidden Burden on Health Systems
Longevity clinics often brand themselves as an alternative to mainstream health care. In practice, they remain dependent on it. Every incidental finding on a scan, every questionable biomarker in a blood test, eventually funnels patients back into hospitals and specialist clinics.
This puts new pressure on already strained health systems. Instead of focusing on proven preventive measures like vaccinations, cancer screenings at recommended ages, or chronic disease management, clinicians must respond to a rising tide of “worried well” patients seeking follow-up for ambiguous test results.
The cost is not merely financial. Overdiagnosis and overtreatment carry real physical risks—biopsies, unnecessary surgeries, and drug side effects—all in pursuit of conditions that may never have posed a threat in the first place.
Overdiagnosis: When More Testing Means Less Health
For decades, medical experts have warned of the risks of overdiagnosis. More testing does not always equal better health. In fact, it often does the opposite.
When people undergo repeated screenings without evidence-based guidelines, the chances of detecting clinically irrelevant conditions skyrocket. This creates a feedback loop: the more abnormalities detected, the more patients feel justified in seeking further testing, reinforcing the cycle.
The longevity industry leans heavily on this psychology. By medicalising the natural ageing process—turning wrinkles, fatigue, or hormonal changes into “problems” to be solved—it fuels demand for interventions that may never improve health outcomes.
Longevity vs. Prevention: A Crucial Distinction
Marketers frequently blur the line between longevity services and preventive medicine. True prevention in public health is simple and proven: immunisation, healthy diet, exercise, and screening for certain cancers at specific ages.
Longevity clinics, however, sell exhaustive test batteries, supplements, and experimental treatments with little evidence they extend life. These are not prevention; they are consumer products wrapped in medical language.
For example, the idea of reversing “biological age” through supplements or blood transfusions may sound scientific but remains unproven. Meanwhile, tried-and-true preventive measures—like cutting smoking rates, reducing obesity, and increasing access to primary care—often receive far less investment or media attention.
Disease Mongering and the Normalisation of Ageism
Perhaps the most insidious impact of the longevity industry is cultural. By framing ageing itself as a disease, it reinforces ageism and pathologises a natural part of life.
The result is a society increasingly uncomfortable with the visible signs of ageing. Normal wrinkles become defects. Ordinary fatigue is reframed as illness. Natural decline becomes failure.
This narrative not only harms older adults but also diverts resources from collective health needs. Instead of investing in equitable access to evidence-based care, we risk funnelling public and private money into the pursuit of individual immortality for those who can afford it.
The Real Path to Healthy Ageing
Despite the hype, the fundamentals of healthy ageing remain accessible and evidence-based. Research consistently shows that regular physical activity, balanced nutrition, quality sleep, and strong social connections contribute more to long life and wellbeing than any experimental longevity hack.
The so-called Blue Zones—regions of the world with exceptionally high rates of centenarians, such as Okinawa in Japan and Sardinia in Italy—illustrate this point. Their longevity is linked not to cutting-edge technology but to plant-based diets, daily movement, and deeply embedded social ties.
Public health experts argue that resources should be channelled into making these evidence-based practices more accessible: affordable nutritious food, walkable communities, robust public health programs, and equitable access to medical care. These are proven investments that improve both length and quality of life across entire populations.
A Call for Regulation and Critical Thinking
The rapid growth of the longevity industry raises urgent questions for policymakers and consumers alike. How should governments regulate direct-to-consumer medical testing? Should companies be allowed to market unproven treatments with promises of life extension? What safeguards exist against exploitation of vulnerable populations fearful of ageing and death?
Regulation will need to balance innovation with consumer protection, ensuring that products are backed by evidence before being sold as medical solutions. At the same time, consumers must develop critical health literacy—learning to question bold claims, understand the risks of overdiagnosis, and distinguish between genuine prevention and expensive hype.
Conclusion: Facing Mortality Honestly
In the end, the longevity industry sells more than supplements and scans. It sells a seductive narrative: that death is optional, that ageing is a disease to be conquered, that immortality might be just one breakthrough away.
But the truth is unchanged. Nobody lives forever. The costs of pretending otherwise—financial, cultural, and medical—are real and mounting.
Society must resist the lure of quick fixes and instead embrace the fundamentals of public health and human connection. Living longer, healthier, and more meaningful lives may not require immortality at all. It may only require a renewed focus on what we already know works.
The pursuit of eternal life is an old story. The challenge now is ensuring it doesn’t become a costly distraction from the real work of building healthier, more equitable societies where ageing is not feared but respected as part of life’s natural arc.
